Roth Capital restated their buy rating on shares of Equillium (NASDAQ:EQ – Free Report) in a report issued on Friday,Benzinga reports. Roth Capital currently has a $12.00 price objective on the stock.
Other research analysts have also issued research reports about the stock. Leerink Partners raised shares of Equillium from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $1.00 to $6.00 in a research note on Thursday, May 28th. Wall Street Zen upgraded shares of Equillium from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Raymond James Financial reissued a “strong-buy” rating and set a $7.00 price target on shares of Equillium in a research report on Thursday, May 28th. Stifel Nicolaus set a $5.00 price target on shares of Equillium in a report on Thursday, May 28th. Finally, Zacks Research raised shares of Equillium from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $7.57.
View Our Latest Analysis on EQ
Equillium Stock Performance
Equillium (NASDAQ:EQ – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. As a group, sell-side analysts predict that Equillium will post -0.21 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Equillium
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC acquired a new stake in shares of Equillium in the 2nd quarter valued at about $35,000. Coastal Bridge Advisors LLC acquired a new position in shares of Equillium during the second quarter worth about $48,000. Dimensional Fund Advisors LP acquired a new position in shares of Equillium during the first quarter worth about $31,000. Virtu Financial LLC grew its holdings in shares of Equillium by 133.4% during the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after buying an additional 13,591 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Equillium during the third quarter worth about $35,000. 27.05% of the stock is owned by institutional investors and hedge funds.
Equillium Company Profile
Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.
Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.
Read More
- Five stocks we like better than Equillium
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.
